Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 7Gastrointestinal 3Dermatologic 3Breast 3Thoracic 2Genitourinary 2Sarcoma 1Plasma cell 1

Conditions

Sarcoma 4Melanoma 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Osteosarcoma 2Gliosarcoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 14Cyclophosphamide 13Carboplatin 12Paclitaxel 8Ifosfamide 8Doxorubicin 8pembrolizumab 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6fludarabine 5Temozolomide 5Specimen Handling 5Radiotherapy 5Cisplatin 5Magnetic Resonance Spectroscopy 4Etoposide 4Docetaxel 4Amifostine 4aldesleukin 3Trastuzumab 3Taxes 3Psychiatric Rehabilitation 3Melphalan 3Fulvestrant 3Bevacizumab 3sodium thiosulfate 2pazopanib 2pamiparib 2palbociclib 2etoposide phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × poly ICLC × Sarcoma × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡